ORIGINAL ARTICLE |
|
Year : 2021 | Volume
: 16
| Issue : 4 | Page : 396-401 |
|
Urinary vascular cell adhesion molecule-1 as a marker of disease activity in lupus nephritis
Shivraj Padiyar1, Theophilus S Vijayakumar2, Samuel Hansdak3, John Mathew1
1 Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India 2 Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India 3 Department of Medicine, Christian Medical College, Vellore, Tamil Nadu, India
Correspondence Address:
Dr. John Mathew Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, Tamil Nadu India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/injr.injr_288_20
|
|
Objectives: The objective of this study is to study the role of urinary vascular cell adhesion molecule-1 (uVCAM-1) as a marker for disease activity in lupus nephritis (LN).
Methodology: This was a diagnostic study where patients with active LN were taken as cases and those without LN were taken as disease controls. uVCAM-1 was correlated with the classes of LN and standard of care markers.
Results: There was a significant difference between the uVCAM-1 values in cases (59.69 [range: 0.07–13752.5]) pg/mg and controls (2.11 [range − 0.11 − 1138.5] pg/mg [P = 0.02]). Maximum levels of VCAM 1 were seen in Class 4 and Class 5 LN (P = 0.96). Although higher renal systemic lupus erythematosus disease activity index score had a higher median value of uVCAM 1, the values were not statistically significant (P = 0.2). There is a positive correlation between the uVCAM1 and anti-double-stranded DNA (anti-dsDNA) levels (r = 0.38) and a negative correlation between VCAM 1 levels and C3 (r = −0.19).The sensitivity of uVCAM1 for determining the disease activity was 65.2%, and the specificity was 75% at a cutoff value of more than 23.8 pg/mg.
Conclusions: uVCAM 1, although not in isolation, but along with the other standard of care markers may be useful in assessing the disease activity.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|